Beximco Pharma


Pharmatech Resources
Concise Prescribing Info
Single or mixed infections caused by ≥2 susceptible organisms; infections caused by organisms resistant to other antibiotics including aminoglycosides, penicillin & cephalosporins. Severe systemic (eg, septicaemia, bacteraemia, peritonitis, infections in immunosuppressed patients w/ haematological or solid tumors & in patients in ICU w/ specific problems eg, infected burns); resp tract (lobar & bronchopneumonia, acute & chronic bronchitis, acute exacerbation of cystic fibrosis, bronchiectasis, empyema); UTI (uncomplicated & complicated urethritis, cystitis, pyelonephritis, prostatitis, epididymitis); skin & soft tissue (eg, infected ulcers, wound infections, abscesses, cellulitis, otitis externa, erysipelas, infected burns); GI (eg, enteric fever, infective diarrhoea); biliary tract (eg, cholangitis, cholecystitis, gall bladder empyema); intra-abdominal (eg, peritonitis, intra-abdominal abscesses); bone & joint (eg, osteomyelitis, septic arthritis); pelvic (eg, salpingitis, endometritis, pelvic inflammatory diseases); & eye & ENT (eg, otitis media, sinusitis, mastoiditis, tonsilitis). Gonorrhoea including urethral, rectal & pharyngeal gonorrhoea caused by β-lactamase producing organisms or organisms moderately sensitive to penicillin.
Dosage/Direction for Use
Adult 250-750 mg bd. Acute infections Duration of treatment: 5-10 days. Generally treatment should be continued for 3 days after signs & symptoms of infection disappeared. Adolescent & childn 7.5-15 mg/kg/day depending upon the severity of infection, administered in 2 divided doses.
May be taken with or without food: May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones.
Special Precautions
History of convulsive disorders; crystalluria. Patients should be well hydrated & avoid excessive alkalinity of urine. Patients w/ known risk factors for QT interval prolongation eg, congenital long QT syndrome, concomitant use of drugs known to prolong QT interval (eg, class IA & III antiarrhythmics, TCAs, macrolides, antipsychotics), uncorrected electrolyte imbalance (eg, hypokalaemia, hypomagnesaemia), elderly, cardiac disease (eg, heart failure, MI, bradycardia). Discontinue use if patient experiences symptoms of peripheral neuropathy. Vision diorders. Not recommended during pregnancy & lactation. Not recommended in childn, growing childn & adolescents.
Adverse Reactions
GI disturbances (eg, nausea, diarrhoea, vomiting, dyspepsia, abdominal pain), disturbances of CNS (eg, dizziness, headache, tiredness, confusion, convulsion), hypersensitivity reactions (eg, skin rashes, pruritus & possible systemic reactions). Joint pain, mild photosensitivity & transient increase in liver enzymes, serum bilirubin, urea or creatinine levels.
Drug Interactions
Elevated plasma conc & prolongation of elimination t½ of theophylline. May interfere absorption w/ antacids containing Mg hydroxide or Al hydroxide. Interferes renal tubular secretion & produces an increase serum level w/ probenecid. Drugs known to prolong QT interval (eg, class IA & III antiarrhythmics, TCAs, macrolides, antipsychotics). Antagonistic combination w/ chloramphenicol.
MIMS Class
ATC Classification
J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Neofloxin tab 250 mg
5 × 10's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in